1.2. Pediatrics

Rifaximin is FDA-approved in children 12 years of age and older for use in managing travelers’ diarrhea due to noninvasive strains of E. coli. The recommended oral rifaximin dose for pediatric patients is 200 mg three times daily for three days. Rifaximin should not be prescribed for use in diarrhea caused by pathogens other than E. coli or complicated by fever or blood in the stool^{1, 6-8}.

The safety and efficacy of rifaximin 200 mg for travelers’ diarrhea in pediatric patients younger than 12 years of age or rifaximin 550 mg for HE or IBS-D in pediatric patients younger than 18 years of age have not been established^{1, 6-8}.